Curcumin as an adjuvant to breast cancer treatment

Anti-Cancer Agents in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 647-656

  Kumar, Parveen ^a   Kadakol, Almesh ^b   Shasthrula, Prashanth Krishna ^a   Mundhe, Nitin Arunrao ^a   Jamdade, Vinayak Sudhir ^a   Barua, Chandana C ^c   Gaikwad, Anil Bhanudas ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

^c Uttar Pradesh Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go Anusandhan Sansthan   (India)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Curcumin; Resistance

Indexed keywords

CASPASE; CURCUMIN; CYCLIN D; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; INTERFERON; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; PACLITAXEL; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ADHESION; CELL CYCLE ARREST; CELL PROLIFERATION; CHEMOSENSITIZATION; DNA REPLICATION; DOWN REGULATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG METABOLISM; HUMAN; INFLAMMATION; MASTECTOMY; METASTASIS; SIGNAL TRANSDUCTION; UPREGULATION; ADJUVANT CHEMOTHERAPY; ANIMAL; BREAST NEOPLASMS; CELL CYCLE; DRUG EFFECTS; FEMALE; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CURCUMIN; FEMALE; HUMANS;

EID: 84930709230     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150101125918     Document Type: Article

References (101)

1. Yeole, B.B.; Kurkure, A.P. An epidemiological assessment of increasing incidence and trends in breast cancer in Mumbai and other sites in India, during the last two decades. Asi. Pac. J. Cancer Prev., 2003, 4(1), 51-56.
2. Richie, R.C.; Swanson, J.O. Breast cancer: A review of the literature. J. Insur. Med., 2003, 35(2), 85-101.
3. Lamartiniere, C.A. Protection against breast cancer with genistein: A component of soy. Am. J. Clin. Nutr., 2000, 71(6 Suppl), 1705S-1707S,1708S-1709S.
4. Snykers, S.; Vanhaecke, T.; De Becker, A.; Papeleu, P.; Vinken, M.; Van Riet, I.; Rogiers, V. Chromatin remodeling agent trichostatin A: A key-factor in the hepatic differentiation of human mesenchymal stem cells derived of adult bone marrow. BMC Develop. Biol., 2007, 7, 24.
5. Giordano, S. H. A review of the diagnosis and management of male breast cancer. Oncologist, 2005, 10(7), 471-479.
6. Ellsworth, R.E.; Decewicz, D.J.; Shriver, C.D.; Ellsworth, D.L. Breast cancer in the personal genomics era. Curr. Genomics., 2010, 11(3), 146-161.
7. Pruthi, S.; Brandt, K.R.; Degnim, A.C.; Goetz, M.P.; Perez, E.A.; Reynolds, C.A.; Schomberg, P.J.; Dy, G.K.; Ingle, J.N. A multidisciplinary approach to the management of breast cancer, part 1: Prevention and diagnosis. Mayo Clin. Proc., 2007, 82(8), 999-1012.
8. Vitiello, D.; Naftolin, F.; Taylor, H.S. Menopause: Developing a rational treatment plan. Gynecol. Endocrinol., 2007, 23(12), 682-691.
9. Euhus, D.M.; Robinson, L. Genetic predisposition syndromes and their management. Surg. Clin. North. Am., 2013, 93(2), 341-362.
10. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature, 1995, 378(6559), 789-792.
11. Wooster, R.; Neuhausen, S.L.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; et al., Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science, 1994, 265(5181), 2088-2090.
12. McLaughlin, S.A. Surgical management of the breast: Breast conservation therapy and mastectomy. Surg. Clin. North Am., 2013, 93(2), 411-428.
13. Wang, X.; Yuan, S.; Wang, J.; Lin, P.; Liu, G.; Lu, Y.; Zhang, J.; Wang, W.; Wei, Y. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo. Toxicol. Appl. Pharmacol., 2006, 215(2), 168-178.
14. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin and cancer: An "old-age" disease with an "age-old" solution. Cancer Lett., 2008, 267(1), 133-164.
15. Aggarwal, B. B.; Kumar, A.; Bharti, A. C. Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Res., 2003, 23(1A), 363-398.
16. Levi, M.S.; Borne, R.F.; Williamson, J.S. A review of cancer chemopreventive agents. Curr. Med. Chem., 2001, 8(11), 1349-1362.
17. Surh, Y.J. Anti-tumor promoting potential of selected spice ingredients with antioxidative and anti-inflammatory activities: A short review. Food Chem. Toxicol., 2002, 40(8), 1091-1097.
18. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: A review of preclinical and clinical research. Altern. Med. Rev., 2009, 14(2), 141-153.
19. Tabar, L.; Dean, P.; Chen, T.H.; Yen, A.F.; Chiu, S.H.; Tot, T.; Smith, R.; Duffy, S. The impact of mammography screening on the diagnosis and management of early-phase breast cancer. In Breast Cancer, Francescatti, D.S.; Silverstein, M.J. Eds. Springer New York: 2014; pp 31-78.
20. Fu, Q.; McKnight, R.A.; Yu, X.; Callaway, C.W.; Lane, R.H. Growth retardation alters the epigenetic characteristics of hepatic dual specificity phosphatase 5. FASEB, 2006, 20(12), 2127-2129.
21. Weigelt, B.; Pusztai, L.; Ashworth, A.; Reis-Filho, J.S. Challenges translating breast cancer gene signatures into the clinic. Nat. Rev. Clin. Oncol., 2011, 9(1), 58-64.
22. Gottesman, M.M. Mechanisms of cancer drug resistance. Ann. Rev. Med., 2002, 53, 615-627.
23. DeVita, V.T.J.R.; Chu, E. A history of cancer chemotherapy. Cancer Res., 2008, 68(21), 8643-8653.
24. Sak, K. Chemotherapy and dietary phytochemical agents. Chemother. Res. Pract., 2012, 2012, 282570.
25. Boekhout, A.H.; Beijnen, J.H.; Schellens, J.H. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist, 2006, 11(6), 641-654.
26. Jacob, A.; Wu, R.; Zhou, M.; Wang, P. Mechanism of the antiinflammatory effect of curcumin: ppar-gamma activation. PPAR Res., 2007, 2007, 89369.
27. Ramirez-Tortosa, M.C.; Mesa, M.D.; Aguilera, M.C.; Quiles, J.L.; Baro, L.; Ramirez-Tortosa, C.L.; Martinez-Victoria, E.; Gil, A. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis, 1999, 147(2), 371-378.
28. Naidu, K.A.; Thippeswamy, N.B. Inhibition of human low density lipoprotein oxidation by active principles from spices. Mol. Cell Biochem., 2002, 229(1-2), 19-23.
29. Patro, B.S.; Rele, S.; Chintalwar, G.J.; Chattopadhyay, S.; Adhikari, S.; Mukherjee, T. Protective activities of some phenolic 1, 3-diketones against lipid peroxidation: Possible involvement of the 1, 3-diketone moiety. Chem. Biochem., 2002, 3(4), 364-370.
30. Srivastava, K.C.; Bordia, A.; Verma, S.K. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins. Leukot. Essent. Fatty Acids, 1995, 52(4), 223-227.
31. Srivastava, R.; Puri, V.; Srimal, R.C.; Dhawan, B.N. Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis. Arzneimittelforschung, 1986, 36(4), 715-717.
32. Srivastava, R.; Dikshit, M.; Srimal, R.C.; Dhawan, B.N. Antithrombotic effect of curcumin. Thromb. Res., 1985, 40(3), 413-417.
33. Dikshit, M.; Rastogi, L.; Shukla, R.; Srimal, R. C. Prevention of ischaemia-induced biochemical changes by curcumin & quinidine in the cat heart. Ind. J. Med. Res., 1995, 101, 31-35.
34. Nirmala, C.; Puvanakrishnan, R. Effect of curcumin on certain lysosomal hydrolases in isoproterenol-induced myocardial infarction in rats. Biochem. Pharmacol., 1996, 51(1), 47-51.
35. Nirmala, C.; Puvanakrishnan, R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol. Cell Biochem., 1996, 159(2), 85-93.
36. Arun, N.; Nalini, N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats. Plant Foods Hum. Nutr., 2002, 57 (1), 41-52.
37. Babu, P.S.; Srinivasan, K. Influence of dietary curcumin and cholesterol on the progression of experimentally induced diabetes in albino rat. Mol. Cell Biochem., 1995, 152(1), 13-21.
38. Srinivasan, M. Effect of curcumin on blood sugar as seen in a diabetic subject. Ind. J. Med. Sci., 1972, 26(4), 269-270.
39. Frautschy, S.A.; Hu, W.; Kim, P.; Miller, S.A.; Chu, T.; Harris-White, M.E.; Cole, G.M. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging, 2001, 22(6), 993-1005.
40. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G. M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21 (21), 8370-8377.
41. Phan, T.T.; See, P.; Lee, S.T.; Chan, S.Y. Protective effects of curcumin against oxidative damage on skin cells in vitro: Its implication for wound healing. J. Trauma, 2001, 51(5), 927-931.
42. Morikawa, T.; Matsuda, H.; Ninomiya, K.; Yoshikawa, M. Medicinal foodstuffs. XXIX. Potent protective effects of sesquiterpenes and curcumin from Zedoariae Rhizoma on liver injury induced by D-galactosamine/lipopolysaccharide or tumor necrosis factor-alpha. Biol. Pharm. Bull., 2002, 25(5), 627-631.
43. Awasthi, S.; Srivatava, S.K.; Piper, J.T.; Singhal, S.S.; Chaubey, M.; Awasthi, Y.C. Curcumin protects against 4-hydroxy-2-transnonenal-induced cataract formation in rat lenses. Am. J. Clin. Nutr., 1996, 64 (5), 761-766.
44. Venkatesan, N. Pulmonary protective effects of curcumin against paraquat toxicity. Life Sci., 2000, 66(2), PL21-28.
45. Barthelemy, S.; Vergnes, L.; Moynier, M.; Guyot, D.; Labidalle, S.; Bahraoui, E. Curcumin and curcumin derivatives inhibit Tatmediated transactivation of type 1 human immunodeficiency virus long terminal repeat. Res. Virol., 1998, 149(1), 43-52.
46. Sui, Z.; Salto, R.; Li, J.; Craik, C.; Ortiz de Montellano, P.R. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg. Med. Chem., 1993, 1(6), 415-422.
47. Saleheen, D.; Ali, S.A.; Ashfaq, K.; Siddiqui, A.A.; Agha, A.; Yasinzai, M.M. Latent activity of curcumin against leishmaniasis in vitro. Biol. Pharm. Bull., 2002, 25(3), 386-389.
48. Chen, H.W.; Huang, H.C. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br. J. Pharmacol., 1998, 124(6), 1029-1040.
49. Ringman, J.M.; Frautschy, S.A.; Cole, G.M.; Masterman, D.L.; Cummings, J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alz. Res., 2005, 2(2), 131-136.
50. Shishodia, S.; Sethi, G.; Aggarwal, B.B. Curcumin: Getting back to the roots. Ann. NY Acad Sci., 2005, 1056, 206-217.
51. Jonkers, J.; Derksen, P.W. Modeling metastatic breast cancer in mice. J. Mammary Gland. Biol. Neoplasia., 2007, 12(2-3), 191-203.
52. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. Adv. Exp. Med. Biol., 2007, 595, 1-75.
53. Campbell, F.C.; Collett, G.P. Chemopreventive properties of curcumin. Fut. Oncol., 2005, 1(3), 405-414.
54. Basile, V.; Ferrari, E.; Lazzari, S.; Belluti, S.; Pignedoli, F.; Imbriano, C. Curcumin derivatives: Molecular basis of their anticancer activity. Biochem. Pharmacol., 2009, 78(10), 1305-1315.
55. Wilken, R.; Veena, M.S.; Wang, M.B.; Srivatsan, E.S. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol. Cancer, 2011, 10, 12.
56. Sharma, R.A.; Gescher, A.J.; Steward, W.P. Curcumin: The story so far. Eur. J. Cancer, 2005, 41(13), 1955-1968.
57. Yang, L.; Wu, S.; Zhang, Q.; Liu, F.; Wu, P. 23, 24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria-dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett., 2007, 256(2), 267-278.
58. Moragoda, L.; Jaszewski, R.; Majumdar, A.P. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res., 2001, 21(2A), 873-878.
59. Irving, G.R.; Karmokar, A.; Berry, D.P.; Brown, K.; Steward, W. P. Curcumin: The potential for efficacy in gastrointestinal diseases. Best Pract. Res. Clin. Gastroent., 2011, 25(4-5), 519-534.
60. Park, J.; Conteas, C. N. Anti-carcinogenic properties of curcumin on colorectal cancer. World J. Gastrointest. Oncol., 2010, 2(4), 169-176.
61. Johnson, J.J.; Mukhtar, H. Curcumin for chemoprevention of colon cancer. Cancer Lett., 2007, 255(2), 170-181.
62. Irving, G.R.; Karmokar, A.; Berry, D.P.; Brown, K.; Steward, W. P. Curcumin: The potential for efficacy in gastrointestinal diseases. Best Pract. Res. Clin. Gastroent., 2011, 25(4-5), 519-534.
63. Goel, A.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol., 2008, 75(4), 787-809.
64. Jaiswal, A.S.; Marlow, B.P.; Gupta, N.; Narayan, S. Beta-cateninmediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene, 2002, 21(55), 8414-8427.
65. Banerji, A.; Chakrabarti, J.; Mitra, A.; Chatterjee, A. Effect of curcumin on gelatinase A (MMP-2) activity in B16F10 melanoma cells. Cancer Lett., 2004, 211(2), 235-242.
66. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell Mol. Life Sci., 2008, 65(11), 1631-1652.
67. Jang, Y.H.; Namkoong, S.; Kim, Y.M.; Lee, S.J.; Park, B.J.; Min, D.S. Cleavage of phospholipase D1 by caspase promotes apoptosis via modulation of the p53-dependent cell death pathway. Cell Death Differ., 2008, 15(11), 1782-1793.
68. Shishodia, S.; Chaturvedi, M.M.; Aggarwal, B.B. Role of curcumin in cancer therapy. Curr. Prob. Cancer, 2007, 31(4), 243-305.
69. Ioachim, E.; Charchanti, A.; Briasoulis, E.; Karavasilis, V.; Tsanou, H.; Arvanitis, D.L.; Agnantis, N.J.; Pavlidis, N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. Eur. J. Cancer, 2002, 38(18), 2362-2370.
70. Jia, Y.; Zeng, Z.Z.; Markwart, S.M.; Rockwood, K.F.; Ignatoski, K. M.; Ethier, S.P.; Livant, D.L. Integrin fibronectin receptors in matrix metalloproteinase-1-dependent invasion by breast cancer and mammary epithelial cells. Cancer Res., 2004, 64(23), 8674-8681.
71. Hsu, C. H.; Cheng, A. L., Clinical studies with curcumin. Adv. Exp. Med. Biol., 2007, 595, 471-480.
72. Bayet-Robert, M.; Kwiatkowski, F.; Leheurteur, M.; Gachon, F.; Planchat, E.; Abrial, C.; Mouret-Reynier, M.A.; Durando, X.; Barthomeuf, C.; Chollet, P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol. Ther., 2010, 9(1), 8-14.
73. Kim, H.B.; Kong, M.; Kim, T.M.; Suh, Y.H.; Kim, W.H.; Lim, J. H.; Song, J.H.; Jung, M.H. NFATc4 and ATF3 negatively regulate adiponectin gene expression in 3T3-L1 adipocytes. Diabetes, 2006, 55(5), 1342-1352.
74. Qiao, L.; Schaack, J.; Shao, J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology, 2006, 147(2), 865-874.
75. Iguchi, H.; Ikeda, Y.; Okamura, M.; Tanaka, T.; Urashima, Y.; Ohguchi, H.; Takayasu, S.; Kojima, N.; Iwasaki, S.; Ohashi, R.; Jiang, S.; Hasegawa, G.; Ioka, R. X.; Magoori, K.; Sumi, K.; Maejima, T.; Uchida, A.; Naito, M.; Osborne, T. F.; Yanagisawa, M.; Yamamoto, T. T.; Kodama, T.; Sakai, J. SOX6 attenuates glucose-stimulated insulin secretion by repressing PDX1 transcriptional activity and is down-regulated in hyperinsulinemic obese mice. J. Biol. Chem., 2005, 280(45), 37669-37680.
76. Jiang, M.; Huang, O.; Zhang, X.; Xie, Z.; Shen, A.; Liu, H.; Geng, M.; Shen, K. Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogen-resistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9. Molecules, 2013, 18(1), 701-720.
77. Cho, Y.A.; Lee, W.; Choi, J.S. Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: Possible role of CYP3A4 and Pglycoprotein inhibition by curcumin. Pharmazie, 2012, 67(2), 124-130.
78. Zhou, Q.M.; Wang, X.F.; Liu, X.J.; Zhang, H.; Lu, Y.Y.; Huang, S.; Su, S.B. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur. J. Cancer, 2011, 47(14), 2240-2247.
79. Zhou, Q.M.; Wang, X.F.; Liu, X.J.; Zhang, H.; Lu, Y.Y.; Su, S.B. Curcumin enhanced antiproliferative effect of mitomycin C in human breast cancer MCF-7 cells in vitro and in vivo. Acta Pharmacol. Sin., 2011, 32(11), 1402-1410.
80. Sen, G.S.; Mohanty, S.; Hossain, D.M.; Bhattacharyya, S.; Banerjee, S.; Chakraborty, J.; Saha, S.; Ray, P.; Bhattacharjee, P.; Mandal, D.; Bhattacharya, A.; Chattopadhyay, S.; Das, T.; Sa, G. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFkappaB-p300 cross-talk in favor of p53-p300 in breast cancer. J. Biol. Chem., 2011, 286(49), 42232-42247.
81. Aggarwal, B.B.; Shishodia, S.; Takada, Y.; Banerjee, S.; Newman, R.A.; Bueso-Ramos, C.E.; Price, J.E. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin. Cancer Res., 2005, 11(20), 7490-7498.
82. Chirnomas, D.; Taniguchi, T.; De la Vega, M.; Vaidya, A.P.; Vasserman, M.; Hartman, A.R.; Kennedy, R.; Foster, R.; Mahoney, J.; Seiden, M.V.; D'Andrea, A. D. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther., 2006, 5(4), 952-961.
83. Vinod, B.S.; Antony, J.; Nair, H.H.; Puliyappadamba, V.T.; Saikia, M.; Narayanan, S.S.; Bevin, A.; Anto, R.J. Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil. Cell Death Dis., 2013, 4, e505.
84. Scandlyn, M.J.; Stuart, E.C.; Somers-Edgar, T.J.; Menzies, A.R.; Rosengren, R.J. A new role for tamoxifen in oestrogen receptornegative breast cancer when it is combined with epigallocatechin gallate. Br. J. Cancer, 2008, 99(7), 1056-1063.
85. Verma, S.P.; Salamone, E.; Goldin, B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem. Biophys. Res. Commun., 1997, 233 (3), 692-696.
86. Altenburg, J.D.; Bieberich, A.A.; Terry, C.; Harvey, K.A.; Vanhorn, J.F.; Xu, Z.; Jo Davisson, V.; Siddiqui, R.A. A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer, 2011, 11, 149.
87. Chainani-Wu, N. Safety and anti-inflammatory activity of curcumin: A component of tumeric (Curcuma longa). J. Altern. Complement. Med., 2003, 9(1), 161-168.
88. Mancuso, C.; Barone, E. Curcumin in clinical practice: Myth or reality? Trends Pharmacol. Sci., 2009, 30(7), 333-334.
89. Kiec-Swierczynska, M.; Krecisz, B. Occupational allergic contact dermatitis due to curcumin food colour in a pasta factory worker. Cont. Dermatitis., 1998, 39(1), 30-31.
90. Lopez-Lazaro, M.; Willmore, E.; Jobson, A.; Gilroy, K.L.; Curtis, H.; Padget, K.; Austin, C.A. Curcumin induces high levels of topoisomerase I-and II-DNA complexes in K562 leukemia cells. J. Nat. Prod., 2007, 70(12), 1884-1888.
91. Burgos-Moron, E.; Calderon-Montano, J. M.; Salvador, J.; Robles, A.; Lopez-Lazaro, M. The dark side of curcumin. Int. J. Cancer, 2010, 126(7), 1771-1775.
92. Cridge, B.J.; Larsen, L.; Rosengren, R.J. Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncol. Disc., 2013, 1 (1), 6.
93. Zhu, S.; Moore, T.W.; Morii, N.; Howard, R.B.; Culver, D.; Arrendale, R.F.; Reddy, P.; Evers, T.J.; Zhang, H.; Sica, G.; Chen, Z.G.; Sun, A.; Fu, H.; Khuri, F.R.; Shin, D.M.; Snyder, J. P.; Shoji, M. Synthetic Curcumin Analog UBS Inhibits the Growth of Head and Neck Squamous Cell Carcinoma Xenografts. Curr. Cancer Drug Targ., 2014.
94. Zhou, G.Z.; Zhang, S.N.; Zhang, L.; Sun, G.C.; Chen, X.B. A synthetic curcumin derivative hydrazinobenzoylcurcumin induces autophagy in A549 lung cancer cells. Pharmaceut. Biol., 2014, 52 (1), 111-116.
95. Yu, Y.; Zhang, X.; Qiu, L. The anti-tumor efficacy of curcumin when delivered by size/charge-changing multistage polymeric micelles based on amphiphilic poly(beta-amino ester) derivates. Biomaterials, 2014, 35(10), 3467-3479.
96. Yoon, M.J.; Kang, Y.J.; Lee, J.A.; Kim, I.Y.; Kim, M.A.; Lee, Y. S.; Park, J.H.; Lee, B.Y.; Kim, I.A.; Kim, H.S.; Kim, S.A.; Yoon, A.R.; Yun, C.O.; Kim, E.Y.; Lee, K.; Choi, K.S. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin. Cell Death Dis., 2014, 5, e1112.
97. Sakano, K.; Kawanishi, S., Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch. Biochem. Biophys., 2002, 405(2), 223-230.
98. Jiao, Y.; Wilkinson, J.T.; Di, X.; Wang, W.; Hatcher, H.; Kock, N. D.; D'Agostino, R.Jr.; Knovich, M.A.; Torti, F.M.; Torti, S.V. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood, 2009, 113(2), 462-469.
99. Oetari, S.; Sudibyo, M.; Commandeur, J.N.; Samhoedi, R.; Vermeulen, N.P. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochem. Pharmacol., 1996, 51(1), 39-45.
100. Appiah-Opong, R.; Commandeur, J.N.; Van Vugt-Lussenburg, B.; Vermeulen, N. P. Inhibition of human recombinant cytochrome P450s by curcumin and curcumin decomposition products. Toxicology, 2007, 235(1-2), 83-91.
101. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M.; Pirmohamed, M.; Gescher, A.J.; Steward, W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res., 2004, 10(20), 6847-6854.